Deep Blue Medical Raises $5.6M in Series A Funding

The company plans to use the funds to expand into aesthetic and breast treatments and to strengthen its relationships with key experts and hospital systems.

Deep Blue’s platform is designed to address suture pull-through, a common cause of soft-tissue surgery failure, using its T-Line Mesh, Suture, and Aesthetic Scaffold products.

Mr. Fuqua, formerly Senior Vice President, has strong experience growing medical device startups into successful companies. His background includes quality, regulatory work, product development, and manufacturing. In his new role, he will lead these areas as the company enters its next phase of growth.

Read More:Ray Therapeutics Raises $125M in Series B Funding

"This oversubscribed round reflects strong investor confidence in our platform and the clinical evidence behind it," said CEO Bill Perry. "With 18 peer-reviewed publications, 21 issued patents, and more than 20,000 patented lockstitches and extensions implanted over five years — including multi-center long-term follow-up demonstrating high efficacy and excellent safety — Deep Blue is exceptionally well-positioned to scale. The pipeline is full, the evidence is strong, and the timing is right."  

"Suture pull-through and surgical failure represent a significant, underappreciated problem — and we have a compelling solution," said Mr. Fuqua. "I'm proud of what this team has built and excited about what comes next."  

About Deep Blue Medical Advances

Founded in 2015, by Howard Levinson, Deep Blue Medical Advances develops advanced surgical devices to improve soft tissue repair, including enhanced support, and closure. Its products include T Line Mesh, Sutures and Aesthetic Scaffolds, supported by strong clinical data, and a growing patent portfolio.

Read More:AcuityMD Raises $80M in Series C Funding Led by StepStone Group